Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing systemically administered immunotherapies for cancer and chronic viral infections. The company’s core platform leverages proprietary, attenuated, killed, non-pathogenic Gram-negative bacteria engineered to reduce intravenous toxicity while preserving the ability to activate both innate and adaptive immune responses. This approach is designed to deliver a multi-targeted package of immune-stimulating signals that can be given safely via intravenous infusion, aiming to trigger broad anti-tumor and anti-viral activity. Indaptus Therapeutics’ lead candidate, Decoy20, is being developed for solid tumors such as colorectal, hepatocellular, and pancreatic cancers, as well as non-Hodgkin’s lymphoma, and is also being explored in settings related to chronic viral infections including hepatitis B and HIV. Operating within the healthcare and biotechnology sector, and headquartered in New York, New York, the company occupies a niche in the immuno-oncology and immuno-virology landscape, targeting indications where durable immune-driven responses are a key clinical objective.